#USA #San Diego #Inhibrx Biosciences #ozekibart #INBX-106

Inhibrx Biosciences First Quarter 2026 Financial Overview

In the latest financial update from Inhibrx Biosciences, Inc. (Nasdaq: INBX), the company reported its financial results for the first quarter of 2026 on May 14, showcasing advancements in their clinical pipeline alongside their fiscal health.

Recent Developments

Inhibrx has two promising programs currently underway in clinical trials, highlighting their commitment to advancing biopharmaceutical solutions. One of the key programs, INBRX-106, received attention with the release of updated interim data from the HexAgon study in May 2026. This Phase 2 trial examines the combination of INBRX-106, an OX40 agonist, with pembrolizumab, against pembrolizumab monotherapy in patients with treatment-naïve, PD-L1 positive metastatic or unresectable recurrent Head and Neck Squamous Cell Carcinoma (HNSCC).

The company plans on providing further results regarding the progression-free survival (PFS) data from this randomized trial in the fourth quarter of 2026, which could offer more insights into the efficacy of their treatment approach.

The second program involves ozekibart (INBRX-109), for which updated interim data from a Phase 1/2 study was released in April 2026. This study focuses on the treatment of locally advanced or unresectable colorectal cancer (CRC) in combination with FOLFIRI. Additionally, Inhibrx submitted a Biologics License Application (BLA) to the FDA for ozekibart regarding conventional chondrosarcoma, while also planning a meeting with the FDA later in 2026 to discuss further advancements, including a potential first-line registrational trial for CRC and the feasibility of accelerated regulatory pathways for ozekibart in advanced settings.

Financial Position

As of March 31, 2026, Inhibrx reported cash and cash equivalents totaling $161.7 million, an increase from $124.2 million at the end of 2025. This increase can be attributed to receiving $75.0 million in gross proceeds from a recent amendment to the loan agreement with Oxford Finance LLC.

Research and development (R&D) expenses for the first quarter stood at $25.2 million, a decrease compared to $36.9 million during the same period in 2025. This reduction is primarily linked to lower clinical trial costs as the trial for ozekibart nears completion. Concurrently, personnel-related costs also declined due to a decreased workforce.

General and administrative (G&A) expenses slightly fell to $5.7 million, down from $6.0 million year-over-year, indicating a consistent management of operational costs. However, Inhibrx reported a net loss of $33.4 million or $2.15 per share for the quarter, although this represents an improvement from a $43.3 million loss, or $2.80 per share, recorded in the corresponding quarter of the previous year.

Conclusion

Inhibrx Biosciences continues to make significant strides in its clinical programs while managing its financial resources prudently. As the company anticipates major milestones in its drug development pipeline, stakeholders await if the forthcoming regulatory discussions will unlock new opportunities for their innovative therapies. For more detailed financial information and updates, Inhibrx encourages interested parties to visit their official website: www.inhibrx.com.